Global Influenza Treatment Market

Influenza Treatment Comprehensive Study by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Others), Diagnostic Tests (Viral culture, Serology, Rapid antigen testing, Reverse transcription polymerase chain reaction (RT-PCR), Immunofluorescence assays, Rapid molecular assays), End-users (Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others) Players and Region - Global Market Outlook to 2030

Influenza Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Influenza Treatment
Influenza is a viral infection that attacks the respiratory system involving the nose, throat and lungs. It is commonly called as the flu, but it is not as same as stomach flu viruses that cause diarrhea and vomiting. It mainly attacks young children, older adults, pregnant women and people with chronic disease or a weak immune system. Its symptoms include fever, chills, muscle aches, cough, congestion, runny nose, headaches and fatigue. The treatment of influenza includes antiviral medication, such as oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) or baloxavir (Xofluza). Most circulating strains of influenza have become resistant to drugs such as amantadine and rimantadine (Flumadine), which are older antiviral drugs that are no longer recommended.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.8%


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Influenza Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca Plc (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States), Daiichi Sankyo Company, Limited (Japan), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Mylan N.V. (United States), Natco Pharma Limited (India), Novartis AG (Switzerland), Sanofi S.A. (France) and Teva Pharmaceutical Industries Limited (Israel) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Influenza Treatment market by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil and Others) and Region.



On the basis of geography, the market of Influenza Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnostic Tests, the sub-segment i.e. Viral culture will boost the Influenza Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Influenza Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacy will boost the Influenza Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Focus on Preventive Healthcare

Market Growth Drivers:
Increased Adoption of Influenza Vaccine, Increased Prevalence of Influenza, Rising Regulatory Approvals and Increase in the Healthcare Expenditure

Challenges:
Lack of Health Care Infrastructure in Some Regions

Restraints:
Resistance of Influenza Strains to Drugs

Opportunities:
Growth in the Healthcare Industry, Technological Advancements in the Medical Science and High Growth Potential in Developing Regions

Market Leaders and their expansionary development strategies
In March 2020, WHO launches new global influenza strategy. The goal of the strategy is to prevent seasonal influenza, control the spread of influenza from animals to humans, and prepare for the next influenza pandemic.
In March 2024, Cadila Pharmaceuticals on Monday announced the launch of the Cadiflu Tetra Vaccine which is an advanced Quadrivalent Influenza Vaccine to prevent influenza, a recurrent, widespread, and debilitating viral infection. The vaccine is approved by DCGI for use in adults and children.


Key Target Audience
Influenza Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Peramivir
  • Zanamivir
  • Oseltamivir Phosphate
  • Baloxavir Marboxil
  • Others
By Diagnostic Tests
  • Viral culture
  • Serology
  • Rapid antigen testing
  • Reverse transcription polymerase chain reaction (RT-PCR)
  • Immunofluorescence assays
  • Rapid molecular assays

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Adoption of Influenza Vaccine
      • 3.2.2. Increased Prevalence of Influenza
      • 3.2.3. Rising Regulatory Approvals
      • 3.2.4. Increase in the Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Lack of Health Care Infrastructure in Some Regions
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Influenza Treatment, by Type, Diagnostic Tests, End-users, Distribution Channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Influenza Treatment (Value)
      • 5.2.1. Global Influenza Treatment by: Type (Value)
        • 5.2.1.1. Peramivir
        • 5.2.1.2. Zanamivir
        • 5.2.1.3. Oseltamivir Phosphate
        • 5.2.1.4. Baloxavir Marboxil
        • 5.2.1.5. Others
      • 5.2.2. Global Influenza Treatment by: Diagnostic Tests (Value)
        • 5.2.2.1. Viral culture
        • 5.2.2.2. Serology
        • 5.2.2.3. Rapid antigen testing
        • 5.2.2.4. Reverse transcription polymerase chain reaction (RT-PCR)
        • 5.2.2.5. Immunofluorescence assays
        • 5.2.2.6. Rapid molecular assays
      • 5.2.3. Global Influenza Treatment by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Influenza Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Retail Pharmacy
        • 5.2.4.2. Hospital Pharmacy
        • 5.2.4.3. Others
      • 5.2.5. Global Influenza Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Influenza Treatment (Volume)
      • 5.3.1. Global Influenza Treatment by: Type (Volume)
        • 5.3.1.1. Peramivir
        • 5.3.1.2. Zanamivir
        • 5.3.1.3. Oseltamivir Phosphate
        • 5.3.1.4. Baloxavir Marboxil
        • 5.3.1.5. Others
      • 5.3.2. Global Influenza Treatment by: Diagnostic Tests (Volume)
        • 5.3.2.1. Viral culture
        • 5.3.2.2. Serology
        • 5.3.2.3. Rapid antigen testing
        • 5.3.2.4. Reverse transcription polymerase chain reaction (RT-PCR)
        • 5.3.2.5. Immunofluorescence assays
        • 5.3.2.6. Rapid molecular assays
      • 5.3.3. Global Influenza Treatment by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Influenza Treatment by: Distribution Channel (Volume)
        • 5.3.4.1. Retail Pharmacy
        • 5.3.4.2. Hospital Pharmacy
        • 5.3.4.3. Others
      • 5.3.5. Global Influenza Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Influenza Treatment (Price)
      • 5.4.1. Global Influenza Treatment by: Type (Price)
  • 6. Influenza Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioCryst Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Natco Pharma Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical Industries Limited (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Influenza Treatment Sale, by Type, Diagnostic Tests, End-users, Distribution Channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Influenza Treatment (Value)
      • 7.2.1. Global Influenza Treatment by: Type (Value)
        • 7.2.1.1. Peramivir
        • 7.2.1.2. Zanamivir
        • 7.2.1.3. Oseltamivir Phosphate
        • 7.2.1.4. Baloxavir Marboxil
        • 7.2.1.5. Others
      • 7.2.2. Global Influenza Treatment by: Diagnostic Tests (Value)
        • 7.2.2.1. Viral culture
        • 7.2.2.2. Serology
        • 7.2.2.3. Rapid antigen testing
        • 7.2.2.4. Reverse transcription polymerase chain reaction (RT-PCR)
        • 7.2.2.5. Immunofluorescence assays
        • 7.2.2.6. Rapid molecular assays
      • 7.2.3. Global Influenza Treatment by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Influenza Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Retail Pharmacy
        • 7.2.4.2. Hospital Pharmacy
        • 7.2.4.3. Others
      • 7.2.5. Global Influenza Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Influenza Treatment (Volume)
      • 7.3.1. Global Influenza Treatment by: Type (Volume)
        • 7.3.1.1. Peramivir
        • 7.3.1.2. Zanamivir
        • 7.3.1.3. Oseltamivir Phosphate
        • 7.3.1.4. Baloxavir Marboxil
        • 7.3.1.5. Others
      • 7.3.2. Global Influenza Treatment by: Diagnostic Tests (Volume)
        • 7.3.2.1. Viral culture
        • 7.3.2.2. Serology
        • 7.3.2.3. Rapid antigen testing
        • 7.3.2.4. Reverse transcription polymerase chain reaction (RT-PCR)
        • 7.3.2.5. Immunofluorescence assays
        • 7.3.2.6. Rapid molecular assays
      • 7.3.3. Global Influenza Treatment by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Influenza Treatment by: Distribution Channel (Volume)
        • 7.3.4.1. Retail Pharmacy
        • 7.3.4.2. Hospital Pharmacy
        • 7.3.4.3. Others
      • 7.3.5. Global Influenza Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Influenza Treatment (Price)
      • 7.4.1. Global Influenza Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Influenza Treatment: by Type(USD Million)
  • Table 2. Influenza Treatment Peramivir , by Region USD Million (2018-2023)
  • Table 3. Influenza Treatment Zanamivir , by Region USD Million (2018-2023)
  • Table 4. Influenza Treatment Oseltamivir Phosphate , by Region USD Million (2018-2023)
  • Table 5. Influenza Treatment Baloxavir Marboxil , by Region USD Million (2018-2023)
  • Table 6. Influenza Treatment Others , by Region USD Million (2018-2023)
  • Table 7. Influenza Treatment: by Diagnostic Tests(USD Million)
  • Table 8. Influenza Treatment Viral culture , by Region USD Million (2018-2023)
  • Table 9. Influenza Treatment Serology , by Region USD Million (2018-2023)
  • Table 10. Influenza Treatment Rapid antigen testing , by Region USD Million (2018-2023)
  • Table 11. Influenza Treatment Reverse transcription polymerase chain reaction (RT-PCR) , by Region USD Million (2018-2023)
  • Table 12. Influenza Treatment Immunofluorescence assays , by Region USD Million (2018-2023)
  • Table 13. Influenza Treatment Rapid molecular assays , by Region USD Million (2018-2023)
  • Table 14. Influenza Treatment: by End-users(USD Million)
  • Table 15. Influenza Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 16. Influenza Treatment Clinics , by Region USD Million (2018-2023)
  • Table 17. Influenza Treatment Others , by Region USD Million (2018-2023)
  • Table 18. Influenza Treatment: by Distribution Channel(USD Million)
  • Table 19. Influenza Treatment Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 20. Influenza Treatment Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 21. Influenza Treatment Others , by Region USD Million (2018-2023)
  • Table 22. South America Influenza Treatment, by Country USD Million (2018-2023)
  • Table 23. South America Influenza Treatment, by Type USD Million (2018-2023)
  • Table 24. South America Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 25. South America Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 26. South America Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 27. Brazil Influenza Treatment, by Type USD Million (2018-2023)
  • Table 28. Brazil Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 29. Brazil Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 30. Brazil Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 31. Argentina Influenza Treatment, by Type USD Million (2018-2023)
  • Table 32. Argentina Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 33. Argentina Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 34. Argentina Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Influenza Treatment, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 37. Rest of South America Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 38. Rest of South America Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Influenza Treatment, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Influenza Treatment, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 42. Asia Pacific Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 43. Asia Pacific Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 44. China Influenza Treatment, by Type USD Million (2018-2023)
  • Table 45. China Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 46. China Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 47. China Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 48. Japan Influenza Treatment, by Type USD Million (2018-2023)
  • Table 49. Japan Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 50. Japan Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 51. Japan Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 52. India Influenza Treatment, by Type USD Million (2018-2023)
  • Table 53. India Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 54. India Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 55. India Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 56. South Korea Influenza Treatment, by Type USD Million (2018-2023)
  • Table 57. South Korea Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 58. South Korea Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 59. South Korea Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 60. Taiwan Influenza Treatment, by Type USD Million (2018-2023)
  • Table 61. Taiwan Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 62. Taiwan Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 63. Taiwan Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 64. Australia Influenza Treatment, by Type USD Million (2018-2023)
  • Table 65. Australia Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 66. Australia Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 67. Australia Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Influenza Treatment, by Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 72. Europe Influenza Treatment, by Country USD Million (2018-2023)
  • Table 73. Europe Influenza Treatment, by Type USD Million (2018-2023)
  • Table 74. Europe Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 75. Europe Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 76. Europe Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 77. Germany Influenza Treatment, by Type USD Million (2018-2023)
  • Table 78. Germany Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 79. Germany Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 80. Germany Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 81. France Influenza Treatment, by Type USD Million (2018-2023)
  • Table 82. France Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 83. France Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 84. France Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 85. Italy Influenza Treatment, by Type USD Million (2018-2023)
  • Table 86. Italy Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 87. Italy Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 88. Italy Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 89. United Kingdom Influenza Treatment, by Type USD Million (2018-2023)
  • Table 90. United Kingdom Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 91. United Kingdom Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 92. United Kingdom Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 93. Netherlands Influenza Treatment, by Type USD Million (2018-2023)
  • Table 94. Netherlands Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 95. Netherlands Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 96. Netherlands Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Influenza Treatment, by Type USD Million (2018-2023)
  • Table 98. Rest of Europe Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 99. Rest of Europe Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 100. Rest of Europe Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 101. MEA Influenza Treatment, by Country USD Million (2018-2023)
  • Table 102. MEA Influenza Treatment, by Type USD Million (2018-2023)
  • Table 103. MEA Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 104. MEA Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 105. MEA Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 106. Middle East Influenza Treatment, by Type USD Million (2018-2023)
  • Table 107. Middle East Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 108. Middle East Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 109. Middle East Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 110. Africa Influenza Treatment, by Type USD Million (2018-2023)
  • Table 111. Africa Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 112. Africa Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 113. Africa Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 114. North America Influenza Treatment, by Country USD Million (2018-2023)
  • Table 115. North America Influenza Treatment, by Type USD Million (2018-2023)
  • Table 116. North America Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 117. North America Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 118. North America Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 119. United States Influenza Treatment, by Type USD Million (2018-2023)
  • Table 120. United States Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 121. United States Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 122. United States Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 123. Canada Influenza Treatment, by Type USD Million (2018-2023)
  • Table 124. Canada Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 125. Canada Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 126. Canada Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 127. Mexico Influenza Treatment, by Type USD Million (2018-2023)
  • Table 128. Mexico Influenza Treatment, by Diagnostic Tests USD Million (2018-2023)
  • Table 129. Mexico Influenza Treatment, by End-users USD Million (2018-2023)
  • Table 130. Mexico Influenza Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 131. Influenza Treatment Sales: by Type(K Units)
  • Table 132. Influenza Treatment Sales Peramivir , by Region K Units (2018-2023)
  • Table 133. Influenza Treatment Sales Zanamivir , by Region K Units (2018-2023)
  • Table 134. Influenza Treatment Sales Oseltamivir Phosphate , by Region K Units (2018-2023)
  • Table 135. Influenza Treatment Sales Baloxavir Marboxil , by Region K Units (2018-2023)
  • Table 136. Influenza Treatment Sales Others , by Region K Units (2018-2023)
  • Table 137. Influenza Treatment Sales: by Diagnostic Tests(K Units)
  • Table 138. Influenza Treatment Sales Viral culture , by Region K Units (2018-2023)
  • Table 139. Influenza Treatment Sales Serology , by Region K Units (2018-2023)
  • Table 140. Influenza Treatment Sales Rapid antigen testing , by Region K Units (2018-2023)
  • Table 141. Influenza Treatment Sales Reverse transcription polymerase chain reaction (RT-PCR) , by Region K Units (2018-2023)
  • Table 142. Influenza Treatment Sales Immunofluorescence assays , by Region K Units (2018-2023)
  • Table 143. Influenza Treatment Sales Rapid molecular assays , by Region K Units (2018-2023)
  • Table 144. Influenza Treatment Sales: by End-users(K Units)
  • Table 145. Influenza Treatment Sales Hospitals , by Region K Units (2018-2023)
  • Table 146. Influenza Treatment Sales Clinics , by Region K Units (2018-2023)
  • Table 147. Influenza Treatment Sales Others , by Region K Units (2018-2023)
  • Table 148. Influenza Treatment Sales: by Distribution Channel(K Units)
  • Table 149. Influenza Treatment Sales Retail Pharmacy , by Region K Units (2018-2023)
  • Table 150. Influenza Treatment Sales Hospital Pharmacy , by Region K Units (2018-2023)
  • Table 151. Influenza Treatment Sales Others , by Region K Units (2018-2023)
  • Table 152. South America Influenza Treatment Sales, by Country K Units (2018-2023)
  • Table 153. South America Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 154. South America Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 155. South America Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 156. South America Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 157. Brazil Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 158. Brazil Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 159. Brazil Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 160. Brazil Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 161. Argentina Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 162. Argentina Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 163. Argentina Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 164. Argentina Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 165. Rest of South America Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 166. Rest of South America Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 167. Rest of South America Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 168. Rest of South America Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 169. Asia Pacific Influenza Treatment Sales, by Country K Units (2018-2023)
  • Table 170. Asia Pacific Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 171. Asia Pacific Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 172. Asia Pacific Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 173. Asia Pacific Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 174. China Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 175. China Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 176. China Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 177. China Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 178. Japan Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 179. Japan Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 180. Japan Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 181. Japan Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 182. India Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 183. India Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 184. India Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 185. India Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 186. South Korea Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 187. South Korea Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 188. South Korea Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 189. South Korea Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 190. Taiwan Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 191. Taiwan Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 192. Taiwan Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 193. Taiwan Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 194. Australia Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 195. Australia Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 196. Australia Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 197. Australia Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 198. Rest of Asia-Pacific Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 199. Rest of Asia-Pacific Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 200. Rest of Asia-Pacific Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 201. Rest of Asia-Pacific Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 202. Europe Influenza Treatment Sales, by Country K Units (2018-2023)
  • Table 203. Europe Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 204. Europe Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 205. Europe Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 206. Europe Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 207. Germany Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 208. Germany Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 209. Germany Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 210. Germany Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 211. France Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 212. France Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 213. France Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 214. France Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 215. Italy Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 216. Italy Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 217. Italy Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 218. Italy Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 219. United Kingdom Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 220. United Kingdom Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 221. United Kingdom Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 222. United Kingdom Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 223. Netherlands Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 224. Netherlands Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 225. Netherlands Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 226. Netherlands Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 227. Rest of Europe Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 228. Rest of Europe Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 229. Rest of Europe Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 230. Rest of Europe Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 231. MEA Influenza Treatment Sales, by Country K Units (2018-2023)
  • Table 232. MEA Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 233. MEA Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 234. MEA Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 235. MEA Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 236. Middle East Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 237. Middle East Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 238. Middle East Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 239. Middle East Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 240. Africa Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 241. Africa Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 242. Africa Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 243. Africa Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 244. North America Influenza Treatment Sales, by Country K Units (2018-2023)
  • Table 245. North America Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 246. North America Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 247. North America Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 248. North America Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 249. United States Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 250. United States Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 251. United States Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 252. United States Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 253. Canada Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 254. Canada Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 255. Canada Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 256. Canada Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 257. Mexico Influenza Treatment Sales, by Type K Units (2018-2023)
  • Table 258. Mexico Influenza Treatment Sales, by Diagnostic Tests K Units (2018-2023)
  • Table 259. Mexico Influenza Treatment Sales, by End-users K Units (2018-2023)
  • Table 260. Mexico Influenza Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 261. Influenza Treatment: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Influenza Treatment: by Type(USD Million)
  • Table 273. Influenza Treatment Peramivir , by Region USD Million (2025-2030)
  • Table 274. Influenza Treatment Zanamivir , by Region USD Million (2025-2030)
  • Table 275. Influenza Treatment Oseltamivir Phosphate , by Region USD Million (2025-2030)
  • Table 276. Influenza Treatment Baloxavir Marboxil , by Region USD Million (2025-2030)
  • Table 277. Influenza Treatment Others , by Region USD Million (2025-2030)
  • Table 278. Influenza Treatment: by Diagnostic Tests(USD Million)
  • Table 279. Influenza Treatment Viral culture , by Region USD Million (2025-2030)
  • Table 280. Influenza Treatment Serology , by Region USD Million (2025-2030)
  • Table 281. Influenza Treatment Rapid antigen testing , by Region USD Million (2025-2030)
  • Table 282. Influenza Treatment Reverse transcription polymerase chain reaction (RT-PCR) , by Region USD Million (2025-2030)
  • Table 283. Influenza Treatment Immunofluorescence assays , by Region USD Million (2025-2030)
  • Table 284. Influenza Treatment Rapid molecular assays , by Region USD Million (2025-2030)
  • Table 285. Influenza Treatment: by End-users(USD Million)
  • Table 286. Influenza Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 287. Influenza Treatment Clinics , by Region USD Million (2025-2030)
  • Table 288. Influenza Treatment Others , by Region USD Million (2025-2030)
  • Table 289. Influenza Treatment: by Distribution Channel(USD Million)
  • Table 290. Influenza Treatment Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 291. Influenza Treatment Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 292. Influenza Treatment Others , by Region USD Million (2025-2030)
  • Table 293. South America Influenza Treatment, by Country USD Million (2025-2030)
  • Table 294. South America Influenza Treatment, by Type USD Million (2025-2030)
  • Table 295. South America Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 296. South America Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 297. South America Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 298. Brazil Influenza Treatment, by Type USD Million (2025-2030)
  • Table 299. Brazil Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 300. Brazil Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 301. Brazil Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 302. Argentina Influenza Treatment, by Type USD Million (2025-2030)
  • Table 303. Argentina Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 304. Argentina Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 305. Argentina Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 306. Rest of South America Influenza Treatment, by Type USD Million (2025-2030)
  • Table 307. Rest of South America Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 308. Rest of South America Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 309. Rest of South America Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 310. Asia Pacific Influenza Treatment, by Country USD Million (2025-2030)
  • Table 311. Asia Pacific Influenza Treatment, by Type USD Million (2025-2030)
  • Table 312. Asia Pacific Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 313. Asia Pacific Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 314. Asia Pacific Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 315. China Influenza Treatment, by Type USD Million (2025-2030)
  • Table 316. China Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 317. China Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 318. China Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 319. Japan Influenza Treatment, by Type USD Million (2025-2030)
  • Table 320. Japan Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 321. Japan Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 322. Japan Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 323. India Influenza Treatment, by Type USD Million (2025-2030)
  • Table 324. India Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 325. India Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 326. India Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 327. South Korea Influenza Treatment, by Type USD Million (2025-2030)
  • Table 328. South Korea Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 329. South Korea Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 330. South Korea Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 331. Taiwan Influenza Treatment, by Type USD Million (2025-2030)
  • Table 332. Taiwan Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 333. Taiwan Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 334. Taiwan Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 335. Australia Influenza Treatment, by Type USD Million (2025-2030)
  • Table 336. Australia Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 337. Australia Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 338. Australia Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific Influenza Treatment, by Type USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 342. Rest of Asia-Pacific Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 343. Europe Influenza Treatment, by Country USD Million (2025-2030)
  • Table 344. Europe Influenza Treatment, by Type USD Million (2025-2030)
  • Table 345. Europe Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 346. Europe Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 347. Europe Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 348. Germany Influenza Treatment, by Type USD Million (2025-2030)
  • Table 349. Germany Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 350. Germany Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 351. Germany Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 352. France Influenza Treatment, by Type USD Million (2025-2030)
  • Table 353. France Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 354. France Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 355. France Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 356. Italy Influenza Treatment, by Type USD Million (2025-2030)
  • Table 357. Italy Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 358. Italy Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 359. Italy Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 360. United Kingdom Influenza Treatment, by Type USD Million (2025-2030)
  • Table 361. United Kingdom Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 362. United Kingdom Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 363. United Kingdom Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 364. Netherlands Influenza Treatment, by Type USD Million (2025-2030)
  • Table 365. Netherlands Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 366. Netherlands Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 367. Netherlands Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 368. Rest of Europe Influenza Treatment, by Type USD Million (2025-2030)
  • Table 369. Rest of Europe Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 370. Rest of Europe Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 371. Rest of Europe Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 372. MEA Influenza Treatment, by Country USD Million (2025-2030)
  • Table 373. MEA Influenza Treatment, by Type USD Million (2025-2030)
  • Table 374. MEA Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 375. MEA Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 376. MEA Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 377. Middle East Influenza Treatment, by Type USD Million (2025-2030)
  • Table 378. Middle East Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 379. Middle East Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 380. Middle East Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 381. Africa Influenza Treatment, by Type USD Million (2025-2030)
  • Table 382. Africa Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 383. Africa Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 384. Africa Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 385. North America Influenza Treatment, by Country USD Million (2025-2030)
  • Table 386. North America Influenza Treatment, by Type USD Million (2025-2030)
  • Table 387. North America Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 388. North America Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 389. North America Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 390. United States Influenza Treatment, by Type USD Million (2025-2030)
  • Table 391. United States Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 392. United States Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 393. United States Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 394. Canada Influenza Treatment, by Type USD Million (2025-2030)
  • Table 395. Canada Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 396. Canada Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 397. Canada Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 398. Mexico Influenza Treatment, by Type USD Million (2025-2030)
  • Table 399. Mexico Influenza Treatment, by Diagnostic Tests USD Million (2025-2030)
  • Table 400. Mexico Influenza Treatment, by End-users USD Million (2025-2030)
  • Table 401. Mexico Influenza Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 402. Influenza Treatment Sales: by Type(K Units)
  • Table 403. Influenza Treatment Sales Peramivir , by Region K Units (2025-2030)
  • Table 404. Influenza Treatment Sales Zanamivir , by Region K Units (2025-2030)
  • Table 405. Influenza Treatment Sales Oseltamivir Phosphate , by Region K Units (2025-2030)
  • Table 406. Influenza Treatment Sales Baloxavir Marboxil , by Region K Units (2025-2030)
  • Table 407. Influenza Treatment Sales Others , by Region K Units (2025-2030)
  • Table 408. Influenza Treatment Sales: by Diagnostic Tests(K Units)
  • Table 409. Influenza Treatment Sales Viral culture , by Region K Units (2025-2030)
  • Table 410. Influenza Treatment Sales Serology , by Region K Units (2025-2030)
  • Table 411. Influenza Treatment Sales Rapid antigen testing , by Region K Units (2025-2030)
  • Table 412. Influenza Treatment Sales Reverse transcription polymerase chain reaction (RT-PCR) , by Region K Units (2025-2030)
  • Table 413. Influenza Treatment Sales Immunofluorescence assays , by Region K Units (2025-2030)
  • Table 414. Influenza Treatment Sales Rapid molecular assays , by Region K Units (2025-2030)
  • Table 415. Influenza Treatment Sales: by End-users(K Units)
  • Table 416. Influenza Treatment Sales Hospitals , by Region K Units (2025-2030)
  • Table 417. Influenza Treatment Sales Clinics , by Region K Units (2025-2030)
  • Table 418. Influenza Treatment Sales Others , by Region K Units (2025-2030)
  • Table 419. Influenza Treatment Sales: by Distribution Channel(K Units)
  • Table 420. Influenza Treatment Sales Retail Pharmacy , by Region K Units (2025-2030)
  • Table 421. Influenza Treatment Sales Hospital Pharmacy , by Region K Units (2025-2030)
  • Table 422. Influenza Treatment Sales Others , by Region K Units (2025-2030)
  • Table 423. South America Influenza Treatment Sales, by Country K Units (2025-2030)
  • Table 424. South America Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 425. South America Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 426. South America Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 427. South America Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 428. Brazil Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 429. Brazil Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 430. Brazil Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 431. Brazil Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 432. Argentina Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 433. Argentina Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 434. Argentina Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 435. Argentina Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 436. Rest of South America Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 437. Rest of South America Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 438. Rest of South America Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 439. Rest of South America Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 440. Asia Pacific Influenza Treatment Sales, by Country K Units (2025-2030)
  • Table 441. Asia Pacific Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 442. Asia Pacific Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 443. Asia Pacific Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 444. Asia Pacific Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 445. China Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 446. China Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 447. China Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 448. China Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 449. Japan Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 450. Japan Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 451. Japan Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 452. Japan Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 453. India Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 454. India Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 455. India Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 456. India Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 457. South Korea Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 458. South Korea Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 459. South Korea Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 460. South Korea Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 461. Taiwan Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 462. Taiwan Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 463. Taiwan Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 464. Taiwan Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 465. Australia Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 466. Australia Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 467. Australia Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 468. Australia Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 469. Rest of Asia-Pacific Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 470. Rest of Asia-Pacific Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 471. Rest of Asia-Pacific Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 472. Rest of Asia-Pacific Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 473. Europe Influenza Treatment Sales, by Country K Units (2025-2030)
  • Table 474. Europe Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 475. Europe Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 476. Europe Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 477. Europe Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 478. Germany Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 479. Germany Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 480. Germany Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 481. Germany Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 482. France Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 483. France Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 484. France Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 485. France Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 486. Italy Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 487. Italy Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 488. Italy Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 489. Italy Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 490. United Kingdom Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 491. United Kingdom Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 492. United Kingdom Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 493. United Kingdom Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 494. Netherlands Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 495. Netherlands Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 496. Netherlands Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 497. Netherlands Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 498. Rest of Europe Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 499. Rest of Europe Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 500. Rest of Europe Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 501. Rest of Europe Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 502. MEA Influenza Treatment Sales, by Country K Units (2025-2030)
  • Table 503. MEA Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 504. MEA Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 505. MEA Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 506. MEA Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 507. Middle East Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 508. Middle East Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 509. Middle East Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 510. Middle East Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 511. Africa Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 512. Africa Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 513. Africa Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 514. Africa Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 515. North America Influenza Treatment Sales, by Country K Units (2025-2030)
  • Table 516. North America Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 517. North America Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 518. North America Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 519. North America Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 520. United States Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 521. United States Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 522. United States Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 523. United States Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 524. Canada Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 525. Canada Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 526. Canada Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 527. Canada Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 528. Mexico Influenza Treatment Sales, by Type K Units (2025-2030)
  • Table 529. Mexico Influenza Treatment Sales, by Diagnostic Tests K Units (2025-2030)
  • Table 530. Mexico Influenza Treatment Sales, by End-users K Units (2025-2030)
  • Table 531. Mexico Influenza Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 532. Influenza Treatment: by Type(USD/Units)
  • Table 533. Research Programs/Design for This Report
  • Table 534. Key Data Information from Secondary Sources
  • Table 535. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Influenza Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Influenza Treatment: by Diagnostic Tests USD Million (2018-2023)
  • Figure 6. Global Influenza Treatment: by End-users USD Million (2018-2023)
  • Figure 7. Global Influenza Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Influenza Treatment Share (%), by Country
  • Figure 9. Asia Pacific Influenza Treatment Share (%), by Country
  • Figure 10. Europe Influenza Treatment Share (%), by Country
  • Figure 11. MEA Influenza Treatment Share (%), by Country
  • Figure 12. North America Influenza Treatment Share (%), by Country
  • Figure 13. Global Influenza Treatment: by Type K Units (2018-2023)
  • Figure 14. Global Influenza Treatment: by Diagnostic Tests K Units (2018-2023)
  • Figure 15. Global Influenza Treatment: by End-users K Units (2018-2023)
  • Figure 16. Global Influenza Treatment: by Distribution Channel K Units (2018-2023)
  • Figure 17. South America Influenza Treatment Share (%), by Country
  • Figure 18. Asia Pacific Influenza Treatment Share (%), by Country
  • Figure 19. Europe Influenza Treatment Share (%), by Country
  • Figure 20. MEA Influenza Treatment Share (%), by Country
  • Figure 21. North America Influenza Treatment Share (%), by Country
  • Figure 22. Global Influenza Treatment: by Type USD/Units (2018-2023)
  • Figure 23. Global Influenza Treatment share by Players 2023 (%)
  • Figure 24. Global Influenza Treatment share by Players (Top 3) 2023(%)
  • Figure 25. Global Influenza Treatment share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 29. BioCryst Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. BioCryst Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2023
  • Figure 33. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 35. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 37. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 39. Natco Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 40. Natco Pharma Limited (India) Revenue: by Geography 2023
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 43. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 44. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 45. Teva Pharmaceutical Industries Limited (Israel) Revenue, Net Income and Gross profit
  • Figure 46. Teva Pharmaceutical Industries Limited (Israel) Revenue: by Geography 2023
  • Figure 47. Global Influenza Treatment: by Type USD Million (2025-2030)
  • Figure 48. Global Influenza Treatment: by Diagnostic Tests USD Million (2025-2030)
  • Figure 49. Global Influenza Treatment: by End-users USD Million (2025-2030)
  • Figure 50. Global Influenza Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 51. South America Influenza Treatment Share (%), by Country
  • Figure 52. Asia Pacific Influenza Treatment Share (%), by Country
  • Figure 53. Europe Influenza Treatment Share (%), by Country
  • Figure 54. MEA Influenza Treatment Share (%), by Country
  • Figure 55. North America Influenza Treatment Share (%), by Country
  • Figure 56. Global Influenza Treatment: by Type K Units (2025-2030)
  • Figure 57. Global Influenza Treatment: by Diagnostic Tests K Units (2025-2030)
  • Figure 58. Global Influenza Treatment: by End-users K Units (2025-2030)
  • Figure 59. Global Influenza Treatment: by Distribution Channel K Units (2025-2030)
  • Figure 60. South America Influenza Treatment Share (%), by Country
  • Figure 61. Asia Pacific Influenza Treatment Share (%), by Country
  • Figure 62. Europe Influenza Treatment Share (%), by Country
  • Figure 63. MEA Influenza Treatment Share (%), by Country
  • Figure 64. North America Influenza Treatment Share (%), by Country
  • Figure 65. Global Influenza Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • AstraZeneca Plc (United Kingdom)
  • BioCryst Pharmaceuticals, Inc. (United States)
  • Daiichi Sankyo Company, Limited (Japan)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Mylan N.V. (United States)
  • Natco Pharma Limited (India)
  • Novartis AG (Switzerland)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Limited (Israel)
Select User Access Type

Key Highlights of Report


Mar 2024 225 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Influenza Treatment Market Quantitative research analysis
Global Influenza Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca Plc (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States), Daiichi Sankyo Company, Limited (Japan), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Mylan N.V. (United States), Natco Pharma Limited (India), Novartis AG (Switzerland), Sanofi S.A. (France) and Teva Pharmaceutical Industries Limited (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Focus on Preventive Healthcare" is seen as one of major influencing trends for Influenza Treatment Market during projected period 2023-2030.
The Influenza Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Influenza Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Topical Use Acne Treatment Comprehensive Study by Type (Inflammatory Acne, Cystic Acne, Post-Surgical/Wound Acne), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Type (...
$ 3750
Sacroiliitis Treatment Comprehensive Study by Type (Medication, Pain relievers, Muscle relaxants, TNF inhibitors, Joint Injections, Radiofrequency denervation, Electrical stimulation, Joint fusion), ...
$ 3450
Leishmaniasis Treatment Comprehensive Study by Application (Cutaneous leishmaniasis, Visceral leishmaniasis, Mucocutaneous leishmaniasis), Drug Type (Pentavalent antimonials (Sodium stibogluconate, S...
$ 3750
Phage Therapy Comprehensive Study by Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Route of Administration (Oral, Topical), Targeted Bacteria (Escherichia coli...
$ 3750
Respiratory Virus Infection Drugs Comprehensive Study by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate, Others), Disease Type (COVID...
$ 3750
Behcet's Disease Treatment Comprehensive Study by Type (Anti-inflammatory Medications (Ibuprofen), Topical Ointments (Corticosteroid), Immunosuppressive Medications), Route of Administration (Oral, I...
$ 3750